… Consequently, the therapeutic landscape is becoming increasingly complex. This review …
of care for targeted therapies in lung cancer with driver molecular alterations and future …

… the major molecular alterations in NSCLC and the corresponding therapeutic options. … on
targeted therapy options in advanced and metastatic NSCLC with oncogenic driver alterations. …

… Significant correlations between driver gene alterations and therapeutic outcomes of … urgent
clinical need to applicate effective, targeted therapies. Hence, molecular diagnostic methods…

… This article focuses on driver mutations and epigenetic alterations in association with … of
targeted inhibitors and known drug resistance, review advances in major targeted therapies with …

… Concurrent alterations in driver genes were identified as … who harbouring concurrent driver
gene alterations, compared to … carry co-occurring alterations of other driver genes that have a …

… therapy in the context of oncogenic driver alterations. We previously conducted registry
studies on targeted therapies for NSCLC with ROS1, HER2, BRAF, and RET alterations [14., 15., …

… The oncogenic alterations in HER2, MET and FGFR2 have … driver alterations in GC. Therefore,
IHC and FISH are strongly supported as diagnostic platforms for these targeted therapies. …

… a driver alteration treated with a targeted agent had a median survival of 3.5 years; 313 with
a driver who did not receive targeted therapy … 361 without an identified driver had a median …

… to targeted drugs. Several molecular alterations have been defined as “driver mutations”.
These … It has a widely defined role in the occurrence of driver mutations. Up till now EGFR gene …

… driver alterations. These molecular profiling efforts have made it possible to exploit the …
of molecularly targeted therapies. Selection of patients for targeted therapies is becoming …